Italia markets closed

JNJ Jun 2025 165.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,27000,0000 (0,00%)
Alla chiusura: 11:31AM EDT
Schermo intero
Chiusura precedente4,2700
Aperto4,2700
Denaro2,8000
Domanda5,1000
Prezzo d'esercizio165,00
Scadenza2025-06-20
Min-Max giorno4,2700 - 4,2700
Contratto - Min-MaxN/D
Volume1
Open Interest705
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA